Updated Findings With Ruxolitinib in Polycythemia Vera
Jean-Jacques Kiladjian, MD, PhD, discusses the 5-year follow-up results from the RESPONSE trial, where more than 65% of patients with polycythemia vera still remained on treatment with ruxolitinib.
Jean-Jacques Kiladjian, MD, PhD, professor of clinical pharmacology at Paris Diderot University, discusses the 5-year follow-up results from the RESPONSE trial, where more than 65% of patients with polycythemia vera (PV) still remained on treatment with ruxolitinib (Jakafi).
In addition, more than 74% of patients who achieved a primary response maintained this response, Kiladjian says. Of the patients who achieved a complete hematologic response, 54% maintained that response as well.
Kiladjian says he was pleased to see that molecular response was achieved in these patients as the meanJAK2
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
